an open-label, 1-year extension study of the long-term safety and efficacy of once-daily oros? hydromorphone in patients with chronic cancer pain非盲,1年扩展每日一次的长期安全性和有效性的研究奥罗斯 hydromorphone慢性癌症疼痛患者.pdfVIP

  • 6
  • 0
  • 约8.58万字
  • 约 13页
  • 2017-09-05 发布于上海
  • 举报

an open-label, 1-year extension study of the long-term safety and efficacy of once-daily oros? hydromorphone in patients with chronic cancer pain非盲,1年扩展每日一次的长期安全性和有效性的研究奥罗斯 hydromorphone慢性癌症疼痛患者.pdf

an open-label, 1-year extension study of the long-term safety and efficacy of once-daily oros? hydromorphone in patients with chronic cancer pain非盲,1年扩展每日一次的长期安全性和有效性的研究奥罗斯 hydromorphone慢性癌症疼痛患者

BMC Palliative Care BioMed Central Research article Open Access An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain 1,2 3 4 Magdi Hanna , Alberto Tuca and

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档